Dispensed, pharma, GlaxoSmithKline, Value-Based Care, Biotech, Medicine, Drug prices, Health, BI Prime, GSK

A top exec at GlaxoSmithKline gave us an inside look at the $100 billion pharma giant’s experiment with a new way of getting paid for medicines (GSK)

By

GSK Pharma companies need to move to new ways of getting paid for their products, said Jack Bailey, president of US pharmaceuticals for the $100 billion British drugmaker GlaxoSmithKline. GlaxoSmithKline has been experimenting with a new approach for three to four years. Called value-based care, it means that instead of getting paid per pill, GSK […]

MustHaves.LA a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for us to earn fees by linking to Amazon.com and affiliated sites.